Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes

被引:34
|
作者
De Blasio, Miles J. [1 ,2 ]
Huynh, Nguyen [1 ,3 ]
Deo, Minh [1 ]
Dubrana, Leslie E. [1 ]
Walsh, Jesse [1 ]
Willis, Andrew [1 ]
Prakoso, Darnel [1 ,2 ]
Kiriazis, Helen [4 ]
Donner, Daniel G. [4 ]
Chatham, John C. [5 ]
Ritchie, Rebecca H. [1 ,3 ,6 ,7 ]
机构
[1] Baker Heart & Diabet Inst, Heart Failure Pharmacol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sch BioSci, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[4] Baker Heart & Diabet Inst, Expt Cardiol, Melbourne, Vic, Australia
[5] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[6] Monash Univ, Dept Med, Melbourne, Vic, Australia
[7] Monash Univ, Cent Clin Sch, Dept Diabet, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
type; 1; diabetes; diabetic cardiomyopathy; cardiomyocyte hypertrophy; cardiac fibrosis; diastolic dysfunction; BETA-N-ACETYLGLUCOSAMINE; PROTEIN O-GLCNACYLATION; OXIDATIVE STRESS; CONTRACTILE DYSFUNCTION; HEXOSAMINE BIOSYNTHESIS; DIASTOLIC DYSFUNCTION; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; HEART-FAILURE; UP-REGULATION;
D O I
10.3389/fphys.2020.00124
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The incidence of diabetes and its association with increased cardiovascular disease risk represents a major health issue worldwide. Diabetes-induced hyperglycemia is implicated as a central driver of responses in the diabetic heart such as cardiomyocyte hypertrophy, fibrosis, and oxidative stress, termed diabetic cardiomyopathy. The onset of these responses in the setting of diabetes has not been studied to date. This study aimed to determine the time course of development of diabetic cardiomyopathy in a model of type 1 diabetes (T1D) in vivo. Diabetes was induced in 6-week-old male FVB/N mice via streptozotocin (55 mg/kg i.p. for 5 days; controls received citrate vehicle). At 2, 4, 8, 12, and 16 weeks of untreated diabetes, left ventricular (LV) function was assessed by echocardiography before post-mortem quantification of markers of LV cardiomyocyte hypertrophy, collagen deposition, DNA fragmentation, and changes in components of the hexosamine biosynthesis pathway (HBP) were assessed. Blood glucose and HbA1c levels were elevated by 2 weeks of diabetes. LV and muscle (gastrocnemius) weights were reduced from 8 weeks, whereas liver and kidney weights were increased from 2 and 4 weeks of diabetes, respectively. LV diastolic function declined with diabetes progression, demonstrated by a reduction in E/A ratio from 4 weeks of diabetes, and an increase in peak A-wave amplitude, deceleration time, and isovolumic relaxation time (IVRT) from 4-8 weeks of diabetes. Systemic and local inflammation (TNF alpha, IL-1 beta, CD68) were increased with diabetes. The cardiomyocyte hypertrophic marker Nppa was increased from 8 weeks of diabetes while beta-myosin heavy chain was increased earlier, from 2 weeks of diabetes. LV fibrosis (picrosirius red; Ctgf and Tgf-beta gene expression) and DNA fragmentation (a marker of cardiomyocyte apoptosis) increased with diabetes progression. LV Nox2 and Cd36 expression were elevated after 16 weeks of diabetes. Markers of the LV HBP (Ogt, Oga, Gfat1/2 gene expression), and protein abundance of OGT and total O-GlcNAcylation, were increased by 16 weeks of diabetes. This is the first study to define the progression of cardiac markers contributing to the development of diabetic cardiomyopathy in a mouse model of T1D, confirming multiple pathways contribute to disease progression at various time points.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] OVER-EXPRESSION OF GLYOXALASE-1 PREVENTS DIABETIC CARDIOMYOPATHY IN A MOUSE MODEL OF TYPE 1 DIABETES
    Vulesevic, B.
    Ahmadi, A.
    McNeill, B.
    Milne, R. W.
    Suuronen, E. I.
    CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (10) : S202 - S202
  • [2] Characterization of diabetic neuropathy progression in a mouse model of type 2 diabetes mellitus
    De Gregorio, Cristian
    Contador, David
    Campero, Mario
    Ezquer, Marcelo
    Ezquer, Fernando
    BIOLOGY OPEN, 2018, 7 (09):
  • [3] Diabetic cardiomyopathy: Recent evidence from mouse models of type 1 and type 2 diabetes
    Severson, DL
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2004, 82 (10) : 813 - 823
  • [4] Cardiomyopathy and Diastolic Dysfunction in the Embryo and Neonate of a Type 1 Diabetic Mouse Model
    Niamh Corrigan
    Ann Treacy
    Derek P. Brazil
    Fionnuala M. McAuliffe
    Reproductive Sciences, 2013, 20 : 781 - 790
  • [5] Cardiomyopathy and Diastolic Dysfunction in the Embryo and Neonate of a Type 1 Diabetic Mouse Model
    Corrigan, Niamh
    Treacy, Ann
    Brazil, Derek P.
    McAuliffe, Fionnuala M.
    REPRODUCTIVE SCIENCES, 2013, 20 (07) : 781 - 790
  • [6] THE DYNAMIC PROGRESSION OF DIABETIC NEUROPATHY IN THE PERIPHERAL SENSORY LEVEL IN THE TYPE 1 DIABETIC MOUSE MODEL
    Candiotti, K.
    Zhang, Y.
    Gomez, K.
    Yang, J.
    Rodriguez-Blanco, Y. F.
    ANESTHESIA AND ANALGESIA, 2014, 118 : S198 - +
  • [7] MASP-2 deficiency does not prevent the progression of diabetic kidney disease in a mouse model of type 1 diabetes
    Brinck, Holt Charlotte
    Lene, Halkjaer
    Tom, Dudler
    Wilhelm, Schwaeble
    Krarup, Hansen Troels
    Steffen, Thiel
    Appel, Ostergaard Jakob
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2024, 99 (04)
  • [8] Progression of diabetic complications in patients with type 1 diabetes
    Glazunova, A.
    Arutyunova, M.
    Shamkhalova, M.
    Shestakova, M.
    Moysyuk, Y.
    Pinchuk, A.
    Dmitriev, I.
    Arzumanov, S.
    Dedov, I.
    DIABETOLOGIA, 2017, 60 : S207 - S207
  • [9] Smoking and progression of diabetic nephropathy in type 1 diabetes
    Hovind, P
    Rossing, P
    Tarnow, L
    Parving, HH
    DIABETES CARE, 2003, 26 (03) : 911 - 916
  • [10] Smoking and progression of diabetic nephropathy in Type 1 diabetes
    Hovind, P
    Rossing, P
    Tarnow, L
    Parving, HH
    DIABETOLOGIA, 2002, 45 : A361 - A361